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ARTICLE
Leptin induces TNFα-dependent inflammation
in acquired generalized lipodystrophy and
combined Crohn’s disease
Jörn F. Ziegler1,2,13, Chotima Böttcher 1,3,13, Marilena Letizia1,2, Cansu Yerinde1,2, Hao Wu1,2, Inka Freise1,2,
Yasmina Rodriguez-Sillke 1,2, Ani K. Stoyanova1,4, Martin E. Kreis1,4, Patrick Asbach1,5, Desiree Kunkel 1,6,
Josef Priller1,3,7, Ioannis Anagnostopoulos1,8, Anja A. Kühl1,9, Konstanze Miehle10, Michael Stumvoll10,
Florian Tran11, Broder Fredrich11, Michael Forster 11, Andre Franke 11, Christian Bojarski1,2, Rainer Glauben1,2,
Britt-Sabina Löscher 11, Britta Siegmund 1,2,13* & Carl Weidinger 1,2,12,13*
Leptin has been shown to modulate intestinal inflammation in mice. However, clinical evi-
dence regarding its immune-stimulatory potential in human Crohn’s disease remains sparse.
We here describe a patient with the unique combination of acquired generalized lipody-
strophy and Crohn’s disease (AGLCD) featuring a lack of adipose tissue, leptin deficiency
and intestinal inflammation. Using mass and flow cytometry, immunohistochemistry and
functional metabolic analyses, the AGLCD patient was compared to healthy individuals
and Crohn’s disease patients regarding immune cell composition, function and metabolism
and the effects of recombinant N-methionylleptin (rLeptin) were evaluated. We provide
evidence that rLeptin exerts diverse pro-inflammatory effects on immune cell differentiation
and function, including the metabolic reprogramming of immune cells and the induction of
TNFα, ultimately aggravating Crohn’s disease in the AGLCD patient, which can be reversed
by anti-TNFα therapy. Our results indicate that leptin is required for human immune
homeostasis and contributes to autoimmunity in a TNFα-dependent manner.
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The adipokine leptin regulates the differentiation, functionand metabolism of a variety of immune cell subpopula-tions, as well as of intestinal epithelial cells1–3. Likewise,
leptin has been implicated in the pathogenesis of intestinal
inflammation in Crohn’s disease (CD), in which hyperplastic
mesenteric fat (“creeping fat”) wraps inflamed small intestinal
segments4, and acts as a source of leptin and additional adipo-
kines, that can modulate both systemic immune cell composition,
as well as intestinal epithelial cell function in animal models of
colitis5. Previous studies have demonstrated that leptin deficiency
as well as the pharmacologic blockade of the leptin receptor
attenuate disease severity in mouse models of colitis6,7, high-
lighting a potential role for leptin in inflammatory bowel diseases.
Accordingly, leptin was shown to induce the proliferation and
polarization of CD4+ T helper (Th) cells in animal models of
autoimmune diseases8–11, whereas it suppresses the development
and maintenance of regulatory CD4+ T cells12. Furthermore,
rectal application of leptin promotes intestinal inflammation in
mice by activation of the NF-κB pathway in epithelial cells,
suggesting that direct effects of leptin on the epithelium might
contribute to the induction of inflammation in CD as well13.
It recently became evident that the function and metabolism of
immune cells are closely interconnected. Increased glucose
metabolism is required for effector functions such as cytokine
production in pro-inflammatory M1-like macrophages and
T cells, whereas regulatory T cells and immune-suppressive M2-
like macrophages highly depend on lipid oxidation-based meta-
bolism14. Interestingly, leptin has recently been shown to
orchestrate immune cell metabolism and function as it facilitates
anaerobic glycolysis in murine Th17 cells resulting in increased
production of IL-17 and neuronal inflammation in the model of
experimental autoimmune encephalomyelitis, emphasizing a
critical role for leptin at the crosslink of metabolism and function
of immune cells15.
However, human data on the immune modulatory effects of
leptin are limited to extremely rare diseases including (i) congenital
leptin deficiency where T cell hypo-responsiveness, as well as
metabolic dysfunction have been shown to be reversible by leptin
substitution16, and (ii) acquired generalized lipodystrophy17, a
condition with approximately 100 known cases worldwide18.
Lipodystrophy patients suffer from a varying degree of adipocyte
loss, resulting in hypo-leptinemia, severe insulin resistance, fatty
liver and muscular degeneration. Acquired lipodystrophy can
manifest at different ages and loss of adipose tissue can be complete
and has been associated with autoimmunity19. To our knowledge,
no other case of acquired generalized lipodystrophy and combined
Crohn’s disease (AGLCD) has previously been reported. Since the
formation of the aforementioned creeping fat is restricted to small
intestinal CD and cannot be observed in mouse models20, little is
known about the effects of creeping fat-derived leptin on immune
cell differentiation and disease activity in CD.
Here, we describe a 21-year-old Caucasian male with
AGLCD who received daily injections with 2.5 mg recombinant
N-methionylleptin (rLeptin). Deep immune profiling by mass and
flow cytometry and ex vivo functional assays in addition to
clinical assessment before and after rLeptin substitution revealed
distinct pro-inflammatory effects of rLeptin treatment that
result in an aggravation of intestinal inflammation in a TNFα-
dependent manner.
Results
Clinical phenotype of the AGLCD patient. To date, it remains
elusive how mesenteric fat and fat-derived leptin shape systemic
inflammation in CD and very few clinical scenarios exist, in
which the administration of recombinant adipokines is justified
and in which their immune modulatory function can be studied
in human pathophysiology. The AGLCD patient featured a
complete lack of visceral and subcutaneous adipose tissue
(Fig. 1a), absent leptin production (Fig. 1b), and severe intestinal
inflammation (see Supplementary Note 1 and Supplementary
Table 1 for a detailed case report and a summary of autoimmune
serum markers of the AGLCD patient). Of note, none of the
patient’s relatives displayed similar symptoms (Fig. 1c) and no
causative mutation could be detected in genes commonly
associated with generalized lipodystrophy by exome sequencing
(data not shown). The AGLCD patient had initially developed
acquired generalized lipodystrophy at the age of 4 years and had
been diagnosed with CD (Montreal Classification A1 L3 B2+
B3p) at the age of 11 years, thus suffering from an aggressive
variant of CD. As a consequence of generalized lipodystrophy, the
AGLCD patient had subsequently developed fatty liver degen-
eration requiring liver transplantation at the age of 15 years.
Figure 1d summarizes the clinical history of the AGLCD patient
and compiles lipodystrophy-related and Crohn’s-related inter-
ventions and complications.
Altered immune cell composition in the AGLCD patient. In
order to characterize how the absence of fat tissue affects systemic
immune cell composition in the AGLCD patient and to obtain a
baseline of his immunologic makeup, we first compared periph-
eral blood mononuclear cells (PBMCs) of the AGLCD patient
with lymphocytes of healthy donors (HD) and patients with
CD using mass cytometry for a high dimensional immune cell
analysis which allowed us to better discriminate between
lipodystrophy-associated and CD-specific immune cell altera-
tions. Similar to our previously published protocol21, antibodies
against lineage markers for T cells (CD3, CD4, CD8), monocytic
cells (CD11b, CD11c, CD14, EMR1), B cells (CD19) and NK cells
(CD16, CD56), as well as antibodies against functional makers
(CD36, CD163, TREM2, arginase1, CD206), differentiation
markers (CD33, CD40, CD45, CD64, CD95, CD115, CD116,
CD135), homing markers (CD54, CD68, CD103, CCR2, CCR5,
CCR7, CXCR3, MCP-1), activation markers (CD62L, CD83,
CD86, CD124, CD135, HLA-DR, IL-7R), transcription factors
(Tbet, FOXP3), cytokines (IL-6, IL-8, IL-10, TGFβ, TNFα,
IFNγ, GM-CSF) and metabolic markers (CD27, CD38, PD-1,
PD-1 L, ADRP) served for a deep immune profiling of PBMCs
(Supplementary Table 2).
We performed an unsupervised high-dimensional data analysis
of CD45+ cells using the t-distributed stochastic linear embed-
ding (t-SNE) algorithm (Fig. 1e) and compared the frequency of
cell subsets according to their expression levels of classical cell
lineage markers, such as CD11b, CD3, CD4, CD8, CD14, CD19,
and CD56, as well as functional, homing and activation markers,
including CD86, CCR7, and HLA-DR (Fig. 1e, f). The expression
levels of all markers in the different subpopulations were
subsequently compared between healthy donors, CD patients and
the AGLCD patient (Fig. 1g–l). To validate the degree of
reproducibility of our mass cytometric data and to control for
possible batch effects, we compared the expression of 16
overlapping immune markers included in both our mass
cytometry antibody panels, revealing a high correlation between
the two antibody panels, thus confirming the reliability of our
findings (Supplementary Figs. 1 and 2).
In analogy to CD patients, we observed a reduced frequency of
CD8a+CCR7+ (G1) T cells, as well as an increase in CD11b+
CD86+ (G3) cells in the AGLCD patient when compared to healthy
controls, highlighting a pre-activation of monocytes under
inflammatory conditions and thus reflecting CD-induced changes
in immune cell composition (Fig. 1e, f), which were further reflected
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by comparable expression patterns of several differentiation and
functional markers on CD11b+CD86+ cells and CD14+monocytes
of CD patients and the AGLCD patient (Fig. 1g, h).
In contrast, we found a severe reduction of CD14+ monocytes
(G6) and of Tbet+CD56+CD8+ (G4) and Tbet+CD56+CD8−
NK cells (G5) in the AGLCD patient but not in CD patients or
healthy donors (Fig. 1e, f), suggesting that these alterations are
lipodystrophy-specific and at least partially caused by leptin
deficiency as leptin receptor-deficient db/db mice also show
decreased frequencies of NK cells22.
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In comparison to CD patients and healthy donors, we
furthermore detected a high expression of the activation marker
CD38 on CD11b+CD86+, T and NK cells in the AGLCD patient
(Fig. 1g, i–k), which has previously been linked to the development
of lipodystrophy in HIV patients receiving anti-retroviral therapy23
and to intestinal inflammation in human and mice24 as DSS-
induced colitis is attenuated in CD38−/−mice25. Of note, CD38 was
significantly upregulated in CD8+CCR7− T cells of CD patients
underlining a potential disease-propagating role of CD38 in CD.
Furthermore, the AGLCD patient featured a reduced expres-
sion of CCR7 in his T and B cell compartment (Fig. 1i, j, l),
suggesting an additional disturbance of lymphocyte trafficking as
CCR7 has been implicated in the homing of lymphocytes to
adipose tissue26.
To functionally characterize the lymphocytes in the AGLCD
patient, we stimulated PBMCs of the AGLCD patient, CD
patients or healthy donors with ionomycin/PMA or LPS and
determined TNFα and IFNγ production by flow cytometry
(Supplementary Table 3 and Supplementary Fig. 3). As shown in
Fig. 2a, b, we observed that the frequencies and mean
fluorescence intensity (MFI) levels of TNFα and IFNγ producing
CD4+ and CD8+ T, NK cells and CD14+monocytes were similar
in cells isolated from the AGLCD patient when compared to CD
patients and healthy donors. Likewise, the frequency of FOXP3
expressing CD4+ T cells was comparable in the AGLCD patient
and healthy donors (Supplementary Fig. 4).
Impaired NK and T cell differentiation in the AGLCD patient.
Since we had found reduced frequencies of NK cells in the
AGLCD patient (Fig. 1e, f) using mass cytometry, we further
characterized his NK cell compartment by flow cytometry. Here,
we found lower frequencies of NK cells expressing the cytotoxic
molecules perforin and granzyme B, as well as a lower perforin
expression in the AGLCD patient in comparison to healthy
donors and CD patients. In contrast, CD patients displayed a
significantly higher frequency of granzyme B+ NK cells (p <
0.001) and an increased expression level of granzyme B (p < 0.05)
when compared to healthy donors, whereas perforin expression
was similar in both groups (Fig. 2c). In addition, we observed a
disturbed pattern of CD56/CD16 expression in the AGLCD
patient’s NK cells compared to a healthy individual (Supple-
mentary Fig. 4). These data indicate that the absence of fat tissue
and therefore fat tissue-derived adipokines results in phenotypic
and functional alterations of NK cells.
As the absent storage capacity of fat in adipocytes leads to
hypertriglyceridemia in lipodystrophy patients19 and it has been
shown that intracellular accumulation of lipid droplets impairs
the killing capacity of cytotoxic NK cells by metabolic
reprogramming with subsequent downregulation of granzyme
B27, we next measured the lipid droplet content in various
immune cell subsets. As shown in Fig. 2d, the AGLCD patient
displayed a higher deposition of lipid droplets in monocytes, NK
cells and CD8+ T cells when compared to CD patients and
healthy donors. Interestingly, Greineisen et al. have recently
described that lipid droplet accumulation decreases the capacity
of lymphocytes to flux calcium28, which is required to control the
expansion of naïve CD8+ T cells by orchestrating metabolic
programming and inducing glycolysis29. In line with increased
lipid droplets accumulation, we found an impaired calcium
homeostasis in CD8+ T cells (Fig. 2e), suggesting that the
deranged lipid metabolism in the AGLCD patient contributes to
the observed functional and metabolic immune cell dysfunctions.
Please note that due to the very low frequency of NK cells in the
AGLCD patient no reliable calcium measurements or functional
killing assays could be obtained for NK cells. Glucose uptake,
however, was not altered in PBMCs of the AGLCD patient
(Supplementary Fig. 4). The observed changes in immune cell
metabolism in the AGLCD patient were further reflected by the
increased expression of CD38 in T and NK cells, as CD38, a
multifunctional enzyme with nicotinamide adenine dinucleotide
(NAD) nucleosidase activity30, is not only a marker for activated
T cells31, but was also shown to regulate NAD+ metabolism,
oxidative phosphorylation and glutaminolysis in human CD4+
T cells32.
rLeptin-induced TNFα production and immune cell altera-
tions. Since the AGLCD patient suffered from extreme insulin
resistance due to lipodystrophy and consecutive leptin deficiency,
we decided to restart rLeptin substitution, which had previously
been initiated within the compassionate use program for rLeptin
at the University of Leipzig but had been stopped by the patient
months prior admission to our hospital due to incompliance.
The patient received daily subcutaneous injections with 2.5 mg
rLeptin. After 4 days of rLeptin administration, a substantial
serum concentration of leptin could be detected in the AGLCD
patient (Fig. 3a). Consequently, rLeptin substitution reduced the
required insulin concentrations of the patient ∼10-fold and
decreased the amount of lipid droplets in T, NK, and monocytic
cells (Fig. 3b), which was also indicated by a decreased expression
of ADRP, a lipid droplet binding protein (Fig. 3c). In line with
this reduction in intracellular lipid droplet formation, the serum
levels of triglycerides and total cholesterol also dropped and
normalized under treatment with rLeptin (Supplementary Fig. 5).
Strikingly, rLeptin substitution led to an increased pro-
inflammatory activity of distinct immune cells, as reflected by
an upregulation of perforin expression in NK and CD8+ T cells
(Fig. 3d), as well as an increased frequency and MFI of TNFα-
expressing cells after ex vivo stimulation with ionomycin and
Fig. 1 21-year-old male presenting with AGLCD and consecutively altered immune phenotype. The AGLCD patient was compared to Crohn’ disease
patients (CD) and healthy donors (HD). a MRI scans in two different sequences of a CD patient and the AGLCD patient, showing the complete lack of
subcutaneous and visceral adipose tissue in the AGLCD patient. The white star indicates subcutaneous fat in the CD patient, the red star depicts
mesenteric fat (“creeping fat”) with injections of blood vessels wrapping inflamed intestinal segments (comb sign), the white arrows mark inflamed lesions
in the CD patient. The single white arrowhead indicates a fistula in the AGLCD patient, the two white arrowheads depict a subcutaneous abscess, the single
black star highlights the absence of mesenteric fat in the AGLCD patient, the black arrowhead marks free abdominal fluid. b Leptin serum concentrations
assessed by ELISA in the AGLCD patient, CD patients (n= 7) and HD (n= 5) in biologically independent samples. c Family tree of the AGLCD patient.
d Graphical summary of the AGLCD patient’s clinical history. e-l Comparative immune profiling of PBMCs of the AGLCD patient, CD patients (n= 6) and
HD (n= 5) by mass cytometry in biologically independent samples. e two-dimensional projections of single cell data generated by t-SNE of PBMCs.
Desired subpopulations were gated (G1-G6). Heat colors of expression levels of selected markers have been scaled for each marker individually, while red
denotes high and blue low expression. f Boxplots show the frequencies of different cell subsets (G1-G6). g–l Boxplots show mean expression levels
(arbitrary unit) of selected markers in each cell subset. Boxes extend from the 25th to 75th percentiles. Whisker plots show the min (smallest) and max
(largest) values. The line in the box denotes the median. *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed unpaired t-test without correction for multiple
comparison. The source data are provided as a Source Data file.
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PMA (Fig. 3e). In addition to these functional changes, we also
detected an expansion of activated CD11b+CD86+ cells (G3)
seven days after rLeptin application, whereas reduced numbers of
CD8a+CCR7− T cells (G2), CD19+ B cells and CD8a+ NK cells
(G4) were found after treatment with rLeptin (Fig. 3f, g).
In our view, the observed phenotypic and functional changes of
NK cells in response to rLeptin treatment, including a change in
CD56 expression pattern (Supplementary Fig. 6), granzyme B and
perforin expression, as well as cytokine production, demonstrate
that leptin is an important regulator of NK cell differentiation
and function. Accordingly, leptin receptor-deficient mice show
impaired NK cell development and function22, whereas leptin
administration increases the proliferation, cytotoxic capacity and
perforin expression in the human NK cell line YT33. However, as
indicated by the NK cell numbers remaining low even after
rLeptin substitution, other fat tissue-derived factors such as
adipokines and metabolites likely contribute to proper NK cell
development and might be missing in the fat-deficient AGLCD
patient.
Deep immune profiling of PBMCs by mass cytometry showed
additional rLeptin-associated pro-inflammatory phenotypes in
various immune cell subpopulations in the AGLCD patient (Fig. 3c
and Supplementary Fig. 6). For example, in CD11b+CD86+, T and
NK cells, we found a reduced arginase-1 and increased CD86
expression following rLeptin treatment (Fig. 3c). Arginase-1 has
been proposed as a marker for alternatively-activated macro-
phages34 and is an important intrinsic regulator of amino acid
metabolism and glycolysis in innate lymphoid cells type 235.
Furthermore, we observed decreased CD38 expression in T, NK
and CD11b+CD86+ cells following rLeptin administration, which
supports the assumption of leptin-dependent regulations of NAD+
metabolism in these cells with downstream effects on glutaminolysis
and energy metabolism30,32. In addition, we found increased serum
concentrations of several pro-inflammatory, monocyte-derived
cytokines including G-CSF, MIG and MIP-1β upon rLeptin
application (Fig. 3h), suggesting that rLeptin substitution results
in increased activation of myeloid cells.
Metabolic reprogramming of immune cells by adipocytes and
adipokines was shown to trigger specific differentiation programs,
thereby determining their function36,37. Thus, pro-inflammatory
macrophages highly depend on glycolysis for their energy
homeostasis, whereas fatty acid oxidation is a feature of
macrophages with anti-inflammatory properties38. Accordingly,
when we differentiated monocyte-derived macrophages of a
healthy donor in the presence of serum obtained from the
AGLCD patient after rLeptin substitution, cells showed a reduced
mitochondrial respiration when compared to macrophages that
received AGLCD serum without rLeptin (Fig. 3i, j), whereas
their extracellular acidification rates (ECAR) were comparable
(Supplementary Fig. 7). Likewise, in vitro expanded CD8+ T cells
featured an altered oxygen consumption and extracellular
acidification rate after incubation with AGLCD serum substituted
with rLeptin when compared to controls receiving serum of the
AGLCD patient without rLeptin (Supplementary Figs. 8 and 9),
suggesting that leptin directly influences the bioenergetics of
immune cells.
Since intestinal epithelial cells express the leptin receptor39 and
direct effects of leptin on epithelial cells have been reported2, we
wanted to investigate if leptin might influence epithelial barrier
homeostasis in intestinal inflammation by looking at the wound
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healing capacity and epithelial resistance of human intestinal
epithelial cells in vitro. As shown in Fig. 3k leptin administration
improved wound closure in vitro in scratch assays with T84 cells,
without altering epithelial resistance (Fig. 3l, m).
Intestinal inflammation under rLeptin substitution. The high
disease activity of CD observed in our AGLCD patient during
rLeptin substitution and previously developed structural damage,
in particular fistula development, resulted in an abscess that
ultimately led to ileocolonic resection and terminal ileostomy
(Figs. 1d and 4a). Severe inflammation was detected in all resected
intestinal segments (Fig. 4b). Results from immunohistochem-
istry (Supplementary Table 4) showed a massive infiltration of
the intestinal mucosa with TNFα-expressing cells within the
lamina propria of the AGLCD patient when compared to CD
patients (Fig. 4c). In line with our mass cytometry data, we
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furthermore observed a higher infiltration with activated CD86+
cells in the AGLCD patient (Fig. 4d, e), indicating that the
AGLCD patient had a TNFα-dependent inflammatory activity in
his intestine at the time of surgery. Considering our data on the
effects of rLeptin treatment on the AGLCD patient’s PBMCs
(Fig. 3), we therefore hypothesized that rLeptin treatment
induced a TNFα-driven pro-inflammatory immune response in
the intestine, triggering a severe exacerbation of CD.
Stable remission of the AGLCD patient under TNFα−block-
ade. Following surgery, the patient continued rLeptin sub-
stitution to improve insulin sensitivity and subsequently again
developed mucosal inflammation beginning at the terminal
ileostomy, further supporting the concept of rLeptin-driven
intestinal inflammation. Due to the increased production of
TNFα that we had noted upon rLeptin substitution earlier, we
decided to initiate anti-TNFα therapy with adalimumab,
resulting in stable clinical and endoscopic remission after
6 months of therapy (Fig. 4f). Moreover, TNFα blockade not
only inhibited TNFα and IFNγ production in CD4+ and CD8+
T cells but also increased the frequency of FOXP3+CD4+
T cells in the AGLCD patient as determined by flow cytometry
(Fig. 4g–i).
Discussion
In summary, our results shed light on the complex regulatory role
of fat tissue in intestinal inflammation, as well as on the immune
stimulatory effects of rLeptin on human immune cell composi-
tion, function and metabolism (as summarized in Supplementary
Fig. 10). Farooqi et al. have previously demonstrated that leptin
substitution promotes T cell proliferation and cytokine produc-
tion in three patients with congenital leptin deficiency. However,
in the absence of a concomitant inflammatory disease, no
inflammatory response was detected in vivo16. Likewise, Oral
et al. have observed increased TNFα production in PBMCs in a
cohort of 10 patients with generalized lipodystrophy after four
months of treatment with rLeptin without noticing an induction
or exacerbation of comorbid inflammatory diseases and conse-
quently no autoimmune complications were reported40. Our
results now indicate that, in the setting of a pre-existing inflam-
matory condition, leptin therapy fuels inflammation and increa-
ses disease activity in autoimmunity via the induction of TNFα-
producing cells and by metabolically priming immune cells
towards a pro-inflammatory phenotype. Consistently, Javor et al.
have previously speculated that rLeptin substitution might have
contributed to the deterioration of membranoproliferative glo-
merulonephritis by inducing autoimmunity in two patients with
generalized lipodystrophy in a study investigating the effects of
rLeptin substitution on the renal function of lipodystrophic
patients41. Of note, the AGLCD patient received immunosup-
pressive medication throughout our study, which is likely to have
affected his immune cell composition. However, the medication
was not modified during the course of our study and the
described pro-inflammatory effects of rLeptin were observed
despite immunosuppression with mycophenolate mofetil (MMF)
and tacrolimus. Furthermore, we cannot fully exclude that
treatment with MMF contributed to intestinal inflammation in
the AGLCD patient as MMF-therapy has been associated with
chronic diarrhea, which can be reversed by anti-TNFα
therapy42,43. However, we believe that the histologic presence of
granulomas (Supplementary Fig. 11), the fistulizing nature of
inflammation (Fig. 1a), as well as the occurrence of intestinal
autoimmunity prior to the start of MMF strongly argue against
MMF-driven intestinal inflammation in the AGLCD patient,
since none of these features can be observed in MMF-induced
colitis44. Even if we do not consider MMF to trigger intestinal
inflammation in the AGLCD patient, anti-TNF therapy would
have been beneficial both for treating leptin-induced inflamma-
tion, as well as potential side effects caused by MMF.
Since our findings are based on observations in a single patient
with AGLCD with an extremely complicated clinical course
(Fig. 1d), the generalizability of our findings might be limited and
it would be important to further validate our findings in addi-
tional patients with acquired generalized lipodystrophy and
concomitant autoimmune disease, which is unfortunately difficult
to perform due to the extreme rarity of these patients and the
singularity of the AGLCD patient. However, we are convinced
that our results still provide valuable insights regarding the
immune-stimulatory potential of leptin in human intestinal
inflammation, which are supported by observations in mice as
leptin-deficient ob/ob mice are protected from DSS-induced
colitis6 and the pharmacologic inhibition of the leptin receptor
attenuates disease severity in Il10−/− mouse models of colitis7. In
our opinion, leptin thereby does not directly trigger inflammation
(otherwise rLeptin replacement should cause autoimmunity in all
forms of lipodystrophy, which is not the case), but is instead
enhancing autoimmunity by facilitating the production of pro-
inflammatory cytokines such as TNFα and by regulating immune
cell differentiation and cellular expansion of auto-reactive lym-
phocytes. In addition, our observations also argue in favor of a
broader role of leptin for proper immune cell function as leptin
deficiency is associated with a decreased and impaired NK
compartment both in the AGLCD patient and leptin receptor-
deficient db/db mice22, suggesting that leptin-deficiency might be
considered as a cause of functional immune deficiency. Accord-
ingly, patients with malnutrition and consecutive low levels of
leptin suffer from an increased susceptibility for severe infections
Fig. 3 Leptin induces pro-inflammatory immune responses in the AGLCD patient and improves wound healing in vitro. a Leptin serum concentrations of the
AGLCD patient before (−) and after (+) 4 days of rLeptin substitution. b–g Flow and mass cytometric analysis of the effects of rLeptin treatment on
PBMCs in the AGLCD patient after 4 and/or 7 days. b Lipid droplet content assessed by BODIPY staining. c Heat map displaying the relative changes in
mean expression (compared to before rLeptin substitution) of various functional markers in different cell subsets (mass cytometry antibody panel B in
Supplementary Table 2) (red, fold change above 2 (increased expression); yellow, fold change = 0.1 (decreased expression)). d Perforin expression
measured as mean fluorescence intensity (MFI). e TNFα-expressing cells and the respective MFI. f Two-dimensional projections of single cell data
generated by t-SNE of mass cytometry data (antibody panel A in Supplementary Table 2) show the effects on (g) frequencies of different cell subsets. Heat
colors of expression levels of selected markers on t-SNE maps have been scaled for each marker individually (red, high expression; blue, low expression).
h Serum levels of different immune cell-derived factors measured by CBA i–j Oxygen consumption rate (OCR) assessed by Seahorse analyses in
monocyte-derived macrophages of a healthy donor differentiated in the presence of serum from the AGLCD patient before (“leptin-free”) and after in vitro
or in vivo leptin/rLeptin substitution (performed in at least triplicates, error bars show ± SEM, two-way ANOVA with post-tests and Holm-Sidak
correction). The corresponding extracellular acidification rates (ECAR) are reported in Supplementary Fig. 7. k Scratch assay with human T84 intestinal
epithelial cells in the presence of leptin to assess in vitro wound healing. l–m Effects of leptin on the transepithelial electrical resistance (TEER) across a
monolayer of T84 cells after challenge with TNFα and IFNγ to induce leakage (error bars show SD). *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed unpaired
t-tests (where applicable). The source data are provided as a Source Data file.
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including leishmaniosis and amiobiasis due to impaired T and
NK cell functions45.
We are aware, that our study does not allow to discriminate
between direct and indirect effects of rLeptin substitution on
immune cells as a variety of cofounding metabolic factors could
contribute to the observed immune stimulatory function of leptin
in the AGLCD patient including the leptin-mediated regulation of
appetite, blood lipids, glucose and insulin sensitivity. However,
Reis and colleagues could recently unambiguously show, that
leptin has direct primary effects on the function and differ-
entiation of lymphocytes in intestinal autoimmunity as leptin-
receptor deficient CD4+ T cells from Leprfl/fl-CD4-Cremice fail to
induce intestinal inflammation in transfer models of colitis46.
Accordingly, our group has observed a significantly delayed onset
of colitis in scid mice after the transfer of CD4+ T cells from
Leptin-receptor deficient db/db mice due to a defective produc-
tion of inflammation-promoting cytokines including IFNγ11
further supporting the pro-inflammatory function of leptin in
inflammatory bowel disease.
Our results furthermore help to better understand the complex
role of mesenteric fat in intestinal inflammation, as it is difficult
to study in animal models. Remarkably, Paul et al. have pre-
viously described that leptin is elevated in creeping fat of Crohn’s
disease patients47. Accordingly, CD patients with a high burden
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Fig. 4 TNFα-driven intestinal inflammation during rLeptin treatment is reversed by anti-TNFα therapy. a–e Sustained inflammation under rLeptin
substitution and previously acquired structural damage (stenosis and fistula-induced abscess) made proctocolectomy and ileal resection necessary 16 days
after initiation of rLeptin therapy. The specimen (a) was analyzed histologically by H&E staining (scale bar depicts 100 µm) (b), showing severe
inflammation, and by immunohistochemistry (IHC; c–e). cMicroscopic pictures of IHC staining for TNFα and CD206 in gut tissue from the AGLCD patient
and a Crohn’s disease (CD) patient (The scale bar depicts 20 µm, images were recorded using an AxioImager Z1 from Zeiss). d Additional pictures of IHC
staining for different immune cell markers (recorded with the Vectra3 system from PerkinElmer, the scale bar displays 20 µm) and (e) quantification of
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biologically independent CD control patients was compared to the AGLCD patient (n= 1); for TNFα and CD206 stainings a total of 9 samples of n= 6
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tissues were derived from different anatomical locations, blinded analysis). The box extends from the 25th to 75th percentiles. Whisker plots show the min
(smallest) and max (largest) values. The line in the box denotes the median. f–i Following surgery, rLeptin treatment was continued and the patient
presented with new inflammation beginning at the terminal ileostomy. The clinical decision was made to initiate anti-TNFα therapy while continuing rLeptin
substitution, resulting in clinical and endoscopic remission of Crohn’s disease. f Comparison of pictures taken during endoscopy before starting anti-TNFα
therapy and six months later. g–i Flow cytometric analysis of the effects of anti-TNFα therapy on (g) TNFα and (h) IFNγ production after ex vivo
stimulation, as well as (I) the expression of the transcription factors FOXP3 and RORγt (“before anti-TNFα” combines data from three different time
points). Error bars on column charts display the standard deviation (SD). The source data are provided as a Source Data file.
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of creeping fat also display elevated levels of leptin in the serum
and the amount of visceral fat is directly correlated with a higher
disease activity48. In line with this observation that creeping fat
serves as a local source for leptin and other pro-inflammatory
cytokines, Coffey and colleagues have recently registered in a
small retrospective study that a radical resection of the mesentery
and creeping fat in CD patients increases the recurrence free
survival of patients49. Our group has previously observed in mice,
that intestinal inflammation and subsequent bacterial transloca-
tion into the mesenteric fat induces the local production of leptin
by adipocytes in a TLR-dependent manner in DSS treated wild-
type mice but not in Myd88−/− mice50. Given the high infiltra-
tions of creeping fat with lymphocytes such as CD8+ T cells and
monocytes51, it is plausible to argue that local leptin production
affects the differentiation, as well as the functionality of fat
residing lymphocytes, especially in regard of the observation that
T cells express leptin receptors and that leptin receptor-deficient
T cells fail to induce colitis in mice11,46. However, additional
studies are required to decipher the immune-modulatory func-
tion of creeping fat in the pathogenesis of Crohn’s disease which
is likely to consist of cumulative effects of additional adipokines
and metabolites that are secreted by creeping fat.
Taken together, we believe that our findings might have
important implications for the treatment of patients receiving
rLeptin substitution. Since acquired generalized lipodystrophy is
associated with autoimmune and inflammatory diseases in about
25% of cases19, there may be more lipodystrophy patients in
whom rLeptin therapy is accompanied by an increased activity of
a concomitant inflammatory disease. Therefore, our study pro-
vides first evidence that in such cases anti-TNFα therapy should
be considered to control autoimmunity while maintaining rLeptin
substitution for the metabolic control of lipodystrophy.
Methods
Ethical regulations. Written informed consent was obtained from all patients and
healthy volunteers and included the consent to publish clinical information
potentially identifying individuals. All experiments were approved by the institu-
tional review board of the Charité–Universitätsmedizin Berlin and conducted
accordingly. The authors complied to all relevant ethical regulations for research
involving human participants.
Enzyme-linked immunosorbent assay (ELISA). Serum was obtained from per-
ipheral blood of the AGLCD patient before and after rLeptin (metreleptin from
Aegerion Pharmaceuticals) treatment, as well as from 7 CD patients and 5 healthy
controls. Serum levels of leptin were determined using the Human Leptin DuoSet
ELISA Kit (R&D Systems).
Isolation of peripheral blood mononuclear cells. Heparinized blood was
obtained from the AGLCD patient at different time points before and after leptin
reconstitution. Blood of healthy donors, and CD patients served as controls.
PBMCs were isolated by density gradient centrifugation using Biocoll (Merck).
Cells were either frozen in RPMI 1640 (ThermoFisher Scientific) substituted with
20% fetal bovine serum (FBS; Sigma) and 10% dimethyl sulfoxide (Sigma) and
stored in liquid nitrogen or used directly. For mass cytometry, cells were fixed and
frozen using SmartTube buffer and subsequently stored at −80 °C according to our
previously published protocol21.
Intracellular barcoding for mass cytometry. SmartTube buffer-fixed PBMCs of
the AGLCD patient before and after rLeptin substitution, as well as cells of 6 CD
patients and 5 HD were thawed and subsequently stained with premade combi-
nations of six different palladium isotopes: 102Pd, 104Pd, 105Pd, 106Pd, 108Pd, and
110Pd (Cell-ID 20-plex Pd Barcoding Kit, Fluidigm). After 30 min staining at room
temperature (RT), individual samples were washed twice with cell staining buffer
(0.5% bovine serum albumin in PBS, containing 2 mM EDTA). Samples were
pooled together, washed and further stained with antibodies. Anti-human anti-
bodies (Supplementary Table 2) were purchased either pre-conjugated to metal
isotopes (Fluidigm) or from commercial suppliers in purified form and conjugated
in house using the MaxPar X8 kit (Fluidigm) according to the manufacturer’s
protocol.
Surface and intracellular staining for mass cytometry. After cell barcoding,
washing and pelleting, the combined samples were re-suspended in 100 µl of
antibody cocktail against surface markers (Supplementary Table 2) and incubated
for 30 min at 4 °C. Then, cells were washed twice with cell staining buffer. For
intracellular staining, the stained (non-stimulated) cells were then incubated in
fixation/permeabilization buffer (Fix/Perm Buffer, eBioscience) for 60 min at 4 °C.
Cells were then washed twice with permeabilization buffer (eBioscience). The
samples were then stained with antibody cocktails against intracellular molecules
(Supplementary Table 2) in permeabilization buffer for 1 h at 4 °C. Cells were
subsequently washed twice with permeabilization buffer and incubated overnight
in 2% methanol-free formaldehyde solution (ThermoFisher). Fixed cells were then
washed and re-suspended in 1 ml iridium intercalator solution (Fluidigm) for 1 h at
RT. Next, the samples were washed twice with cell staining buffer and then twice
with ddH2O (Fluidigm). Cells were pelleted and kept at 4 °C until CyTOF
measurement.
CyTOF measurement. Cells were analyzed using a CyTOF2 upgraded to Helios
specifications, with software version 6.5.236. The instrument was tuned according
to the manufactures instructions with tuning solution (Fluidigm) and measurement
of EQ four element calibration beads (Fluidigm) containing 140/142Ce, 151/153Eu,
165Ho, and 175/176Lu served as a quality control for sensitivity and recovery.
Directly prior to analysis cells were re-suspended in ddH2O, filtered (20 µm Cell-
trix, Sysmex), counted and adjusted to 3–5 × 105 cells/ml. EQ four element cali-
bration beads were added at a final concentration of 1:10 of the sample volume to
be able to normalize the data to compensate for signal drift and day-to-day changes
in instrument sensitivity. Samples were acquired with a flow rate of 300–400
events/s. Lower convolution threshold was set to 400, with noise reduction mode
on and cell definition parameters set at event duration of 10–150. The resulting
flow cytometry standard (FCS) files were normalized and randomized using the
CyTOF software’s internal FCS-Processing module on the non-randomized (‘ori-
ginal’) data. Settings were used according to the default settings in the software with
time interval normalization (100 s/minimum of 50 beads) and passport version 2.
Intervals with less than 50 beads per 100 s were excluded from the resulting fcs-file.
Cytobank (www.cytobank.org) was used for initial manual gating on live single
cells, de-barcoding and viSNE to generate t-SNE maps. FCS files containing the
t-SNE embedding as additional two parameters were exported from Cytobank for
downstream exploratory and statistical analyses using GraphPad Prism 6.
Flow cytometry. For the assessment of cytokine production, PBMCs of the
AGLCD patient before and after rLeptin substitution, as well as PBMCs from 5 CD
patients and 6 HD were thawed and cultured for 4 h in RPMI 1640 supplemented
with 10% fetal bovine serum and containing 20 ng/ml phorbol 12-myristate
13-acetate (PMA; Sigma-Aldrich) and 1 µg/ml ionomycin (Sigma-Aldrich) or
100 ng/ml lipopolysaccharide (Sigma-Aldrich). Brefeldin A (10 µg/ml; Sigma-
Aldrich) was added for 2 h prior to harvesting. Cells were then stained for viability
using a fixable dye (LIVE/DEAD™ aqua; ThermoFisher Scientific or Zombie
Violet™; BioLegend). Subsequently, lineage markers (Supplementary Table 3) were
stained and the Foxp3 Staining Set (ThermoFisher Scientific) was applied for
fixation and intracellular and intranuclear staining according to the manufacturer’s
protocol (Supplementary Table 3). Samples were measured using a Canto II flow
cytometer (BD Bioscience). Data were analyzed using the FlowJo software package
V10.1 (FlowJo, LLC).
Lipid droplet formation. Thawed PBMCs were incubated for 30 min with 0.2 µg/
ml BODIPY dye (ThermoFisher Scientific) and subsequently stained and analyzed
by flow cytometry, as described above. The difference of mean fluorescence
intensity (MFI) between BODIPY stained and all-but-BODIPY-stained samples
(ΔMFI) served as a measure of lipid droplet content.
Glucose influx. To assess glucose uptake in immune cells, PBMCs of the AGLCD
patient or a HD were glucose starved for 30 min in PBS. Subsequently, 100 µM of
the fluorescent glucose analog 2-NBDG (ThermoFisher Scientific) was added to the
cells and the MFI of 2-NBDG was assessed in different immune cell subsets using
flow cytometry. The ΔMFI calculates as described for BODIPY experiments.
Calcium measurements. For calcium measurements, thawed PBMCs of a HD and
the AGLCD patient were loaded for 30 min with the calcium sensing dye Fluo-4
AM (2 µg/ml; ThermoFisher Scientific) and subsequently stained for lineage
markers. Calcium influx was measured by flow cytometry as previously descri-
bed52. The experiment was performed in technical duplicates. Data were analyzed
with FlowJo V8.8.7.
Cytometric bead array. Concentrations of G-CSF, MIG, MCP-1 and MIP-1β were
measured in serum of the AGLCD patient before and 4 days after rLeptin sub-
stitution by using the FlowCytomix multi-plex kit from eBioscience according to
the manufacturer’s protocol. Data were analyzed using the FCAP Array™ software
V3.0 from BD Biosciences.
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Seahorse analysis. Monocytes, CD4+ or CD8+ T cells were isolated from PBMCs
of healthy donors using bead-based positive selection kits for CD14+, CD4+, or
CD8+ cells, respectively (Miltenyi Biotec). Monocytes were polarized into mac-
rophages by adding 10 ng/ml GM-CSF (PeproTech) to the medium, while T cells
were activated by stimulation with plate bound anti-CD3 (from eBioscience, clone
OKT3) and anti-CD28 (from BD Bioscience, clone CD28.2) antibodies for 3 days
and subsequently expanded for 4 days in media containing 20 ng/ml IL-2
(PeproTech). Throughout all experiments, RPMI 1640 media was supplemented
either with 10% serum obtained from the AGLCD patient before or after rLeptin
reconstitution (±rLeptin), with AGLCD serum (−rLeptin) that had been supple-
mented with 1 µg/ml leptin in vitro or with serum from healthy donors (HD). After
6 or 7 days of culture, the oxygen consumption rate and the extracellular acid-
ification rate was assessed in at least triplicates on a 96-well Seahorse FX plate
reader using the Cell Mito Stress Test Kit (Agilent).
Histopathology. Paraffin blocks of intestinal tissues derived from the AGLCD
patient and 6–11 samples from different anatomical sites of 3 to 7 CD patients were
cut and stained with hematoxylin and eosin (H&E) or by immunohistochemistry
using antibodies listed in Supplementary Table 4. For antibody detection, the Opal
4-Color Manual IHC Kit (PerkinElmer) was used. Multispectral images were
acquired using a Vectra® 3 imaging system (PerkinElmer). Positive cells were
quantified in 10 high power fields (field of vision in ×400 original magnification) by
inForm software (PerkinElmer). All evaluations were performed in a blinded
manner. For the acquisition of immunofluorescence images depicted in Fig. 4d an
AxioImager Z1 (Zeiss) was used.
Scratch assay. Human T84 colon epithelial cells were obtained from ATCC and
cultured in 24-well plates and scratches were induced using small pipet tips. 1 µg/
ml recombinant human leptin or vehicle was added (Peprotech). Pictures of each
scratch were taken at the start and end (8 days or until first scratch was closed)
using the Axiocam 105-color camera on a Zeiss Primovert microscope. Scratch
areas were determined using the MiToBo Scratch Assay Analyzer (ImageJ) and
changes in scratch area (Δarea) were normalized to the mean Δarea of the
control group.
Transepithelial electric resistance measurements. Human T84 cells were cul-
tured as a monolayer on transwell inserts (5-µm pores from Sigma) placed in a 24-
well plate containing DMEM high glucose medium (4.5 g/l glucose; from Ther-
moFisher Scientific), 10% FBS and 1% penicillin/streptomycin. At baseline, 1 µg/ml
leptin or vehicle (PBS) was added to cells. To induce epithelial leakage, 2 ng/ml
recombinant human TNFα and 2 ng/ml IFNγ (both from Peprotech) were added to
the medium. Electrical resistance was measured between an electrode in the well
and an electrode in the transwell at baseline, after 24 and 48 h, respectively.
Transepithelial electric resistance (TEER) was determined as the measured elec-
trical resistance minus the resistance in uncultured condition (130 Ω) multiplied
with the area of the transwell (0.6 cm2). Results were normalized to the TEER at
baseline of that respective well.
Statistical analysis and graphs. Statistical analysis and graphic data representa-
tion were done using GraphPad Prism version 7.00. Where not indicated other-
wise, two-tailed unpaired t-tests without correction for multiple comparison were
used. For Seahorse analysis, a two-way ANOVA with post-tests comparing against
“AGLCD (-rLeptin)” as control with the Holm-Sidak correction for multiple
comparison was applied. Results were considered statistically significant if p < 0.05.
Exome sequencing. Blood-derived DNA was extracted from the patient, as well as
his healthy mother, sister and brother. Exome enrichment for these four samples
was performed using the IDT xGen Exome Research Panel v 1.0 and 2 × 75 bp
paired-end sequencing was carried out on an Illumina HiSeq 3000. The reads were
mapped against the human reference genome build hg19 using BWA53, sorted,
converted to bam format and indexed with SAMtools54, followed by the removal of
PCR duplicates, local realignment around InDels and base quality score recali-
bration with the GATK55 according to their best practice recommendations fol-
lowed by variant calling and variant quality score recalibration. Variant annotation
and filtering were performed using Alissa Interpret (Agilent).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1b, 1f–l, 2a–e, 3a–e, 3g–h, 3j–k, 3m, 4e, 4g–i and
Supplementary Figs. 1A-E, 2A-C, 4A, 4C-E, 5, 6A-C, 6E, 7, 8 and 9A are provided as a
Source Data file. All mass and flow cytometric data sets, as well as exome sequencing
results generated and analyzed during this study are available from the corresponding
authors on reasonable request that does not include confidential patient information as
the AGLCD patient and his relatives did not consent to a deposition of their personal
data on a public repository.
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